国泰海通证券股份有限公司 关于奥锐特药业股份有限公司 2024 年度持续督导工作现场检查报告 上海证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"）作为奥锐 特药业股份有限公司（以下简称"奥锐特"、"公司"）向不特定对象发行可转换 公司债券的保荐人及持续督导机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所上市公司自律监管指引第 11 号——持续督导》等国家有关法律、 法规和规范性文件的要求和行业公认的业务标准、道德规范，于 2024 年 3 月 3 日和 2025 年 3 月 7 日对奥锐特进行了现场检查，汇总了检查资料。现将本次检 查的情况报告如下： 一、本次现场检查的基本情况 （一）保荐人 国泰海通证券股份有限公司 （二）保荐代表人 王子阳、庞军 （三）现场检查时间 2025 年 3 月 3 日至 2025 年 3 月 7 日 （四）现场检查人员 王子阳、宋凯 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理及内部控制、信息披露、独 立性、与关联方的资金往来、募集资金使用情况、关联交易、对外担保、重大对 外投资、公司经营状况以及承诺履行情况等方面进行了现场 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.8900 | 0.7100 | 25.35 | 0.5200 | | 每股净资产（元） | 5.69 | 4.84 | 17.56 | 4.13 | | 每股公积金(元) | 1.49 | 1.44 | 3.47 | 1.36 | | 每股未分配利润(元) | 2.76 | 2.17 | 27.19 | 1.67 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 14.76 | 12.63 | 16.86 | 10.08 | | 净利润(亿元) | 3.55 | 2.89 | 22.84 | 2.11 | | 净资产收益率(%) | 17.35 | 16.09 | 7.83 | 13.34 | 数据四舍五入，查看更多财务数据>> | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | -- ...

奥锐特药业股份有限公司 2024 年度独立董事述职报告 （钟永成） 作为奥锐特药业股份有限公司(以下简称"公司")的独立董事,本人严 格按照《公司法》《证券法》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上市公司治理准则》等有关法律法规、规范性文件 及公司《章程》《独立董事工作细则》的规定和要求，在 2024 年度勤勉 尽责，忠实履行职务，凭借丰富的会计专业知识和经验，积极参加公司董 事会及各专门委员会会议、股东大会，在董事会日常工作及决策中尽职尽 责，对董事会审议的重大事项发表了独立客观的意见，为董事会的科学决 策提供支撑，促进公司规范运作，有效保障全体股东权益不受损害。现将 本人 2024 年度履职情况报告如下： 一、独立董事的基本情况及独立性说明 （一）本人工作履历、专业背景以及兼职情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域 积累了丰富的经验。本人个人工作履历、专业背景以及兼职情况如下： 本人钟永成,1964年出生,中共党员,本科学历, 2002年7月至今任浙江 中和联合会计师事务所（普通合伙）执行事务合伙人，拥有高级会计师、 注册会计师、注册税务师、注册资产评 ...

（一）本人工作履历、专业背景以及兼职情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域 积累了丰富的经验。本人个人工作履历、专业背景以及兼职情况如下： 本人陈应春，1972年出生，九三学社社员，博士研究生学历，2003 年11月至今任四川大学华西药学院教授、博士生导师。主要从事新型手性 催化剂的设计、合成及不对称催化反应研究以及生理活性物质的设计、合 成等方面的工作。重点在手性有机小分子以及金属配合物催化的不对称合 成领域开展研究并获得了系列成果，在国内外学术期刊上发表SCI论文 200余篇。曾荣获四川省第九届青年科技奖、2011四川省有突出贡献的优 奥锐特药业股份有限公司 2024 年度独立董事述职报告 （陈应春） 作为奥锐特药业股份有限公司(以下简称"公司")的独立董事,本人严 格按照《公司法》《证券法》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上市公司治理准则》等有关法律法规、规范性文件 及公司《章程》《独立董事工作细则》的规定和要求，在 2024 年度勤勉 尽责，忠实履行职务，凭借丰富的专业知识和经验，积极参加公司董事会 及各专门委员会会议、股东大会，在董事会日常工 ...

奥锐特药业股份有限公司 2024 年度独立董事述职报告 （苏为科） （二）独立董事的独立性说明 作为公司的独立董事，本人未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在 利害关系或其他可能妨碍其进行独立客观判断的关系，符合《上市公司独 立董事管理办法》《上海证券交易所上市公司自律监管指引第1号——规 范运作》中对独立董事独立性的相关要求。 二、年度履职情况 （一）出席会议情况 1、报告期内出席董事会、股东大会情况 作为奥锐特药业股份有限公司(以下简称"公司")的独立董事,本人严 格按照《公司法》《证券法》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上市公司治理准则》等有关法律法规、规范性文件 及公司《章程》《独立董事工作细则》的规定和要求，在 2024 年度勤勉 尽责，忠实履行职务，凭借丰富的专业知识和经验，积极参加公司董事会 及各专门委员会会议、股东大会，在董事会日常工作及决策中尽职尽责， 对董事会审议的重大事项发表了独立客观的意见，为董事会的科学决策提 供支撑，促进公司规范运作，有效保障全体股东权益不受损害。现将本人 2024 年度 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,475,741,034.67, representing a year-on-year increase of 16.89% compared to ¥1,262,530,882.14 in 2023[23]. - The net profit attributable to shareholders for 2024 was ¥354,792,033.04, which is a 22.59% increase from ¥289,419,389.73 in 2023[23]. - The net profit after deducting non-recurring gains and losses was ¥350,966,371.48, up 34.25% from ¥261,425,250.85 in 2023[23]. - The basic earnings per share for 2024 was ¥0.89, reflecting a 25.35% increase from ¥0.71 in 2023[24]. - The total assets of the company as of the end of 2024 were ¥3,877,422,385.61, a significant increase of 50.60% from ¥2,574,610,570.52 in 2023[23]. - The weighted average return on equity for 2024 was 17.35%, an increase of 1.26 percentage points from 16.09% in 2023[25]. - The cash flow from operating activities for 2024 was ¥332,405,825.62, down 13.80% from ¥385,605,552.66 in 2023[23]. - The company reported a net profit of ¥82,184,172.26 in Q1 2024, with total revenue of ¥335,623,155.40 for the same period[26]. - The company recorded a net profit of ¥106,407,908.48 in Q2 2024, with revenue of ¥395,033,849.16[26]. - The company achieved a revenue of 1.476 billion yuan in 2024, a year-on-year increase of 16.89%, and a net profit of 355 million yuan, up 22.59% from the previous year[31]. Dividend Policy - The company plans to distribute a cash dividend of RMB 2.90 per 10 shares (including tax), totaling approximately RMB 117,796,550.00, which accounts for 33.20% of the net profit attributable to shareholders for the year 2024[6]. - The company has maintained a consistent cash dividend policy, distributing at least 20% of the distributable profit as cash dividends annually when conditions permit[153][155]. - Over the last three fiscal years, the cumulative cash dividend amount (including tax) was RMB 27,215.07 million, with an average cash dividend payout ratio of 95.47% of the average annual net profit[162]. - The company has not proposed any stock dividends or capital reserve transfers for the 2024 fiscal year, opting to retain undistributed profits for future allocation[156]. - The company’s cash dividend distribution plan for 2024 has been approved by the board and is pending shareholder approval at the annual general meeting[156]. Research and Development - Research and development expenses totaled 146 million yuan, a 6.91% increase year-on-year, with 45 ongoing projects in various drug categories[34]. - The company submitted 29 invention patent applications and received 13 new authorized patents during the reporting period, enhancing its intellectual property portfolio[36]. - The company has established six major engineering technology innovation platforms, enhancing its R&D capabilities[54]. - The company’s R&D investment during the reporting period accounted for 9.92% of its operating revenue, with a net asset ratio of 6.28%[92]. - The company is investing in new product development and technology research to drive innovation and competitiveness in the market[129]. - The company plans to increase R&D expenditure to 143 million yuan in 2024, representing a year-on-year growth of 4.30%[116]. Market Expansion and Strategy - The company is actively expanding its market presence through new product development and regulatory approvals in both domestic and international markets[87]. - The company plans to continue expanding its market share and product offerings in the coming year[66]. - Market expansion plans include entering two new international markets by the end of 2024, aiming for a 30% increase in global sales[130]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million allocated for potential mergers and acquisitions[130]. - The company aims to achieve a revenue growth target of 10% in the next fiscal year, supported by new product launches and market strategies[129]. Environmental Responsibility - The company invested approximately 26.43 million yuan in environmental protection during the reporting period[171]. - The company has implemented various pollution prevention measures, including advanced wastewater and waste gas treatment systems[181][183]. - The company is committed to continuous improvement in environmental management, having obtained ISO 14001:2015 certification for its environmental management system[195]. - The company has established a comprehensive environmental risk emergency mechanism, with the emergency response plan filed with the local environmental authority[187]. - The company has installed online monitoring systems for wastewater and VOCs at discharge points, ensuring compliance with environmental standards[190]. Corporate Governance - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company has a structured decision-making process for profit distribution, requiring board approval and submission to the shareholders' meeting[154]. - The company’s management performance evaluation and incentive mechanisms are overseen by the remuneration and assessment committee of the board[166]. - The company held two shareholder meetings during the reporting period: the first extraordinary meeting in January 2024 and the annual meeting in May 2024[126]. - The company has established a structured compensation policy aimed at attracting and retaining talent, with a focus on performance-based evaluations[150]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[9]. - The company has not faced any substantial impact on its production and operations from major risks during the reporting period[9]. - The company faces risks from international trade environment changes, which could impact its export business[112]. - The company is committed to complying with new industry regulations, including "consistency evaluation of generic drug quality and efficacy" and "centralized procurement," to ensure sustainable profitability[118]. - The company faces risks from intensified competition, particularly from developed countries and emerging markets, which may adversely affect performance if competitive advantages are not maintained[117].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 401,995,270.58, representing a 19.78% increase compared to CNY 335,623,155.40 in the same period last year[4] - Net profit attributable to shareholders was CNY 119,417,662.41, a 45.30% increase from CNY 82,184,172.26 year-over-year[4] - The net profit after deducting non-recurring gains and losses was CNY 112,987,049.26, reflecting a 37.51% increase compared to CNY 82,167,819.58 in the previous year[4] - Basic earnings per share increased by 50.00% to CNY 0.30 from CNY 0.20 in the previous year[4] - Diluted earnings per share also rose by 50.00%, reaching CNY 0.30 compared to CNY 0.20 last year[5] - Total operating revenue for Q1 2025 reached ¥401,995,270.58, a 19.7% increase from ¥335,623,155.40 in Q1 2024[18] - Net profit for Q1 2025 was ¥119,417,662.41, representing a 45.3% increase compared to ¥82,184,172.26 in Q1 2024[19] - Basic and diluted earnings per share for Q1 2025 were both ¥0.30, up from ¥0.20 in Q1 2024[20] - The company reported a total profit of ¥141,535,689.38 for Q1 2025, up from ¥99,108,144.14 in Q1 2024[19] Cash Flow - The net cash flow from operating activities decreased by 71.26%, amounting to CNY 25,705,558.93, down from CNY 89,426,909.65 in the same period last year[4] - Operating cash inflow totaled $397,906,535.95, an increase from $384,208,482.52 year-over-year[23] - Operating cash outflow amounted to $372,200,977.02, compared to $294,781,572.87 in the previous period[23] - Net cash flow from operating activities was $25,705,558.93, down from $89,426,909.65 year-over-year[23] - Cash inflow from investment activities reached $269,306,482.21, significantly higher than $539,851.53 in the prior period[23] - Cash outflow from investment activities was $332,502,382.62, compared to $140,559,046.91 previously[23] - Net cash flow from investment activities was -$63,195,900.41, an improvement from -$140,019,195.38 year-over-year[23] - Cash inflow from financing activities totaled $63,127,400.00, down from $134,514,228.46[24] - Cash outflow from financing activities was $60,151,348.75, compared to $102,191,356.54 in the previous period[24] - Net cash flow from financing activities was $2,976,051.25, a decrease from $32,322,871.92 year-over-year[24] - The ending cash and cash equivalents balance was $736,602,666.87, up from $400,661,672.44 in the prior period[24] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,897,048,240.76, a slight increase of 0.51% from CNY 3,877,422,385.61 at the end of the previous year[5] - The equity attributable to shareholders increased by 4.68% to CNY 2,440,575,900.00 from CNY 2,331,528,721.53 at the end of the previous year[5] - The company's total liabilities decreased to RMB 1,456,472,340.76 from RMB 1,545,893,664.08, reflecting a decrease of approximately 5.8%[14] - Current liabilities decreased to RMB 437,873,952.97 from RMB 532,037,038.75, a reduction of about 17.7%[14] - Non-current assets totaled RMB 1,874,767,784.63, up from RMB 1,830,626,381.82, marking an increase of about 2.4%[13][14] - The company reported a significant increase in fixed assets, which rose to RMB 776,502,004.08 from RMB 606,807,832.86, an increase of approximately 28%[13] - Cash and cash equivalents decreased to RMB 736,602,666.87 from RMB 769,439,830.87, reflecting a decline of approximately 4.8%[12] - Accounts receivable increased to RMB 393,092,250.58 from RMB 349,757,854.06, representing an increase of about 12.4%[13] - Inventory rose to RMB 614,823,371.98 from RMB 589,721,953.58, indicating an increase of approximately 4.3%[13] Non-Recurring Items - Non-recurring gains and losses amounted to CNY 6,430,613.15, with government subsidies contributing CNY 4,178,427.58[6] - Other comprehensive income for Q1 2025 was -¥32,591.37, compared to ¥34,431.97 in Q1 2024[20] Shareholder Information - The company has no significant changes in the top 10 shareholders or their participation in margin trading[11] - There are no new strategies or major product developments mentioned in the conference call[11] Research and Development - Research and development expenses for Q1 2025 were ¥32,087,224.10, compared to ¥28,932,083.97 in Q1 2024, reflecting a 10.4% increase[19]

关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：605116 证券简称：奥锐特 公告编号：2025-032 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 重要内容提示： 会议召开时间：2025 年 05 月 08 日（星期四）15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.ss einfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 （一）会议召开时间：2025 年 05 月 08 日下午 15:00-16:00 （ 二 ） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） （三）会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 04 月 28 日（星期一）至 05 月 07 日（星期三）16:00 前登录上证路演中心网站首页点击"提 ...

奥锐特药业股份有限公司 证券代码：605116 证券简称：奥锐特 公告编号：2025-029 债券代码：111021 债券简称：奥锐转债 关于公司2024 年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号） 和上海证券交易所印发的《上海证券交易所上市公司自律监管指引第 1 号—— 规范运作（2023 年 12 月修订）》（上证发〔2023〕193 号）的规定及奥锐特 药业股份有限公司（以下简称"公司"或"本公司"）《募集资金使用管理制 度》的相关规定，公司现将 2024 年度募集资金存放与实际使用情况专项说明 如下： 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意奥锐特药业股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可〔2024〕924 号），本公 司由主承销 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表…………第 3—3 页 奥锐特公司管理层的责任是提供真实、合法、完整的相关资料，按照《上市 公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《上海证券交易所上市公司自律监管指南第 2 号——业务 办理（2024 年 5 月修订）》（上证函〔2024〕1476 号）的规定编制汇总表，并 保证其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 第 1 页 共 3 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2025〕7475 号 奥锐特药业股份有限公司全体股东： 我们接受委托，审计了奥锐特药业股份有限公司（以下简称奥锐特公司）2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度 的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变 动表，以及财务报表附注，并出具了审计报告。在此基础上，我 ...